Anne‐Marie C. Dingemans
About
Anne‐Marie C. Dingemans is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Anne‐Marie C. Dingemans has authored 368 papers receiving a total of 10.2k indexed citations (citations by other indexed papers that have themselves been cited), including 242 papers in Pulmonary and Respiratory Medicine, 216 papers in Oncology and 59 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Anne‐Marie C. Dingemans's work include Lung Cancer Treatments and Mutations (186 papers), Lung Cancer Research Studies (134 papers) and Lung Cancer Diagnosis and Treatment (102 papers). Anne‐Marie C. Dingemans is often cited by papers focused on Lung Cancer Treatments and Mutations (186 papers), Lung Cancer Research Studies (134 papers) and Lung Cancer Diagnosis and Treatment (102 papers). Anne‐Marie C. Dingemans collaborates with scholars based in Netherlands, United States and Belgium. Anne‐Marie C. Dingemans's co-authors include Lizza Hendriks, Egbert F. Smit, Philippe Lambin, Dirk De Ruysscher, Annemie M.W.J. Schols, Harry J.M. Groen, Gerben Bootsma, Cordula Pitz, Emiel F.�M. Wouters and Peter B. Soeters and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and American Journal of Clinical Nutrition.
In The Last Decade
Anne‐Marie C. Dingemans
353 papers receiving 10.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Anne‐Marie C. Dingemans Netherlands | 54 | 5.7k | 4.9k | 1.9k | 1.8k | 1.5k | 368 | 10.2k | ||
| Jan P. van Meerbeeck Belgium | 63 | 10.6k 1.9× | 5.5k 1.1× | 1.9k 1.0× | 2.5k 1.4× | 1.5k 1.0× | 389 | 15.1k | ||
| Joachim G.J.V. Aerts Netherlands | 53 | 5.5k 1.0× | 4.9k 1.0× | 836 0.4× | 2.0k 1.1× | 759 0.5× | 341 | 10.6k | ||
| James R. Jett United States | 67 | 10.1k 1.8× | 6.8k 1.4× | 3.2k 1.7× | 3.1k 1.7× | 2.4k 1.6× | 277 | 16.6k | ||
| Lorenzo Spaggiari Italy | 49 | 6.3k 1.1× | 2.9k 0.6× | 1.4k 0.7× | 1.6k 0.9× | 1.0k 0.7× | 507 | 10.4k | ||
| Takehiko Fujisawa Japan | 59 | 7.2k 1.3× | 4.8k 1.0× | 787 0.4× | 2.3k 1.3× | 1.3k 0.8× | 261 | 12.2k | ||
| Mizuki Nishino United States | 56 | 6.1k 1.1× | 5.5k 1.1× | 1.7k 0.9× | 1.4k 0.8× | 855 0.6× | 228 | 10.9k | ||
| Corinne Faivre‐Finn United Kingdom | 55 | 8.8k 1.5× | 7.4k 1.5× | 2.5k 1.4× | 1.8k 1.0× | 2.9k 1.9× | 371 | 13.9k | ||
| David S. Ettinger United States | 58 | 4.4k 0.8× | 6.2k 1.3× | 1.0k 0.6× | 2.6k 1.5× | 1.8k 1.2× | 280 | 10.9k | ||
| Marek Ancukiewicz United States | 47 | 4.3k 0.8× | 3.3k 0.7× | 1.4k 0.7× | 2.4k 1.4× | 1.7k 1.1× | 127 | 11.8k | ||
| Kanji Nagai Japan | 61 | 7.1k 1.2× | 5.0k 1.0× | 1.8k 1.0× | 1.6k 0.9× | 1.4k 0.9× | 281 | 12.0k |
Countries citing papers authored by Anne‐Marie C. Dingemans
Since
Specialization
Citations
This map shows the geographic impact of Anne‐Marie C. Dingemans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne‐Marie C. Dingemans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne‐Marie C. Dingemans more than expected).
Fields of papers citing papers by Anne‐Marie C. Dingemans
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Anne‐Marie C. Dingemans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne‐Marie C. Dingemans. The network helps show where Anne‐Marie C. Dingemans may publish in the future.
Co-authorship network of co-authors of Anne‐Marie C. Dingemans
This figure shows the co-authorship network connecting the top 25 collaborators of Anne‐Marie C. Dingemans. A scholar is included among the top collaborators of Anne‐Marie C. Dingemans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne‐Marie C. Dingemans. Anne‐Marie C. Dingemans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Dingemans, Anne‐Marie C., Alessandro Dal Maso, Valentina Guarneri, et al.. (2025). Outcome and safety of lurbinectedin as compassionate use in extensive stage small cell lung cancer: A multicentric international cohort. European Journal of Cancer. 226. 115595–115595.
2.
Moonen, Laura, Jules L. Derks, Lisa M. Hillen, et al.. (2024). Disease relapse in relation to lymph node sampling in lung carcinoid patients. Endocrine Related Cancer. 31(9).
3.
Brandão, Mariana, Jon Zugazagoitia, Anne‐Marie C. Dingemans, et al.. (2024). Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-METexon 14 skipping mutations (METex14).. Journal of Clinical Oncology. 42(16_suppl). 8583–8583.
4.
Moonen, Laura, Jan H. von der Thüsen, Michael A. den Bakker, et al.. (2024). Identification of Defined Molecular Subgroups on the Basis of Immunohistochemical Analyses and Potential Therapeutic Vulnerabilities of Pulmonary Carcinoids. Journal of Thoracic Oncology. 20(4). 451–464.
5.
Zhang, Zhen, Anne‐Marie C. Dingemans, Joachim G.J.V. Aerts, et al.. (2023). Computed tomography-based radiomics for the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer patients treated with immune checkpoint inhibitors. European Journal of Cancer. 183. 142–151.
6.
Dingemans, Anne‐Marie C., Nico van Walree, Franz M.N.H. Schramel, et al.. (2023). High Protein Oral Nutritional Supplements Enable the Majority of Cancer Patients to Meet Protein Intake Recommendations during Systemic Anti-Cancer Treatment: A Randomised Controlled Parallel-Group Study. Nutrients. 15(24). 5030–5030.
7.
Houda, Ilias, Idris Bahce, Chris Dickhoff, et al.. (2023). OA06.03 An International EORTC Survey on Resectability of Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 18(11). S55–S56.
8.
Groenendijk, Floris H., Debbie Robbrecht, Winand N.M. Dinjens, et al.. (2022). Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing. British Journal of Cancer. 127(4). 776–783.
9.
Ruysscher, Dirk K.M. De, et al.. (2021). Dynamics of eligibility criteria for central nervous system metastases in non-small cell lung cancer randomized clinical trials over time: A systematic review. Critical Reviews in Oncology/Hematology. 166. 103460–103460.
10.
Joode, Karlijn de, Daphne W. Dumoulin, Vivian Engelen, et al.. (2020). Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients’ perspective. European Journal of Cancer. 136. 132–139.
11.
Derks, Jules L., Erik Thunnissen, Robert Jan van Suylen, et al.. (2019). Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC). Lung Cancer. 130. 179–186.
12.
Goeje, Pauline L. de, Koen Bezemer, Margaretha E.H. Kaijen-Lambers, et al.. (2019). Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non–small Cell Lung Cancer Patients. Clinical Cancer Research. 25(7). 2219–2227.
13.
Derks, Jules L., Robert Jan van Suylen, Erik Thunnissen, et al.. (2017). Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?. European Respiratory Journal. 49(6). 1601838–1601838.
14.
Wekken, Anthonie J. van der, M F Mastik, Lizza Hendriks, et al.. (2017). Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research. 23(15). 4251–4258.
15.
Hendriks, Lizza, Jules L. Derks, Pieter E. Postmus, et al.. (2015). Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study. European Journal of Cancer. 51(17). 2534–2544.
16.
Kuiper, Justine L., Lizza Hendriks, Anthonie J. van der Wekken, et al.. (2015). Treatment and survival of patients with EGFR -mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis. Lung Cancer. 89(3). 255–261.
17.
Oberije, Cary, Dirk De Ruysscher, Ruud Houben, et al.. (2015). A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients. International Journal of Radiation Oncology*Biology*Physics. 92(4). 935–944.
18.
Lussanet, Quido G. de, Ruud Houben, Dirk De Ruysscher, et al.. (2015). Inter-reader reproducibility of dynamic contrast-enhanced magnetic resonance imaging in patients with non-small cell lung cancer treated with bevacizumab and erlotinib. Lung Cancer. 93. 20–27.
19.
Swarts, Dorian R.A., Mieke E.R. Henfling, Leander Van Neste, et al.. (2013). CD44 and OTP Are Strong Prognostic Markers for Pulmonary Carcinoids. Clinical Cancer Research. 19(8). 2197–2207.
20.
Dingemans, Anne‐Marie C., Ruud H. Brakenhoff, Pieter E. Postmus, & Giuseppe Giaccone. (1997). Detection of cytokeratin-19 transcripts by reverse transcriptase-polymerase chain reaction in lung cancer cell lines and blood of lung cancer patients.. Data Archiving and Networked Services (DANS). 77(3). 213–20.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jan P. van Meerbeeck Breakdown of academic impact, for papers by Joachim G.J.V. Aerts Breakdown of academic impact, for papers by James R. Jett Breakdown of academic impact, for papers by Lorenzo Spaggiari Breakdown of academic impact, for papers by Takehiko Fujisawa Breakdown of academic impact, for papers by Mizuki Nishino Breakdown of academic impact, for papers by Corinne Faivre‐Finn Breakdown of academic impact, for papers by David S. Ettinger Breakdown of academic impact, for papers by Marek Ancukiewicz Breakdown of academic impact, for papers by Kanji Nagai